Saturday, June 25, 2016 5:19:00 PM
It is extremely unlikely that Seymour, Diwan or his wife would be making the kind of money they are making from NNVC. Remember, the 30% mark up on all direct and indirect expenses, plus salary, bonus and friends and family shares. Their families have already cashed out millions.
What would Seymour or Diwan be making in the real world? Would seymour go back to private practice (very unlikely as that has never been his thing) and Diwan wouldn't be making high 6- low 67 figures a year as a lab tech for a big pharma.
The shorts are and day traders are enjoying the slow but steady return they have been able to active for the past 6-7 years due to tyne company's inability to make any real progress.
The reason NNVC goes to outside labs is to make the announcement that they are "working" with these credible institutions and scientists/professors. They are trying to position it as an endorsement of the platform. "We're working with these fine reputable institutions, we must therefore be fine and reputable." But as I've been saying, these are labs for hire and will take on just about ANY outside work. It's surprising that nobody questions why NNVC can say they have no control over when these outside partners will actually get to testing their product, when they are paying them. Just another way to passed the buck for why NOTHING ever gets done. Nothing.
Let's talk about the product. They can't make it. That's what matters. They haven't had any of their test results independently verified. That's what matters. They can not seem to stay focused on any single treatment, regardless of how many times they say it is their singular "laser like" focus.
Flucide, MERS, Dengue, HIV, Ebola…all at a stand still because they are NOW focusing on Herpecide…until they announce Zika.
Wait for it.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM